Dec 8 2009
PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com),
an emerging biotechnology company developing acute care therapeutic drug
products for infectious diseases and cardiovascular disorders, announced
that data will be presented on its heptagonist compounds at the annual
meeting of the American Society of Hematology in New Orleans, Louisiana.
The data will be presented in a poster on December 8, 2009, Abstract
2092, titled: “Novel Antagonists for Low Molecular Weight Heparin and
Heparin-Like Drugs” Lead author and investigator is Dr. Walter
Jeske, of the Cardiovascular Institute of Loyola University Medical
Center, Maywood, Illinois, where the studies were conducted. The poster
describes the activities of several PolyMedix heptagonist compounds and
their abilities to reverse the action of low molecular weight heparin
and heparin-like drugs, enoxaparin and fondaparinux.
PolyMedix’s lead heptagonist compound is PMX-60056, currently in Phase 1
clinical development. On October 27, 2009 PolyMedix announced the
completion of a successful Phase 1B pilot proof of concept human
clinical study with PMX-60056. The results of that study demonstrated
that PMX-60056 completely reversed the anticoagulant effects of heparin
and normalized blood clotting time in human subjects in less than 10
minutes, and that no serious adverse events occurred during the study.
http://www.polymedix.com/